A Phase 3 interventional study of Ripretinib and Sunitinib in Gastrointestinal Stromal Tumors, sponsored by Deciphera Pharmaceuticals, LLC. Active, not recruiting at 121 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.
Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is the only one that started in 2019, is one of 3 in phase 3, and was the 3rd registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:
Ono Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
Deciphera Pharmaceuticals, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 3
First in 2015; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 94 across the 9 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Deciphera Pharmaceuticals, LLC, one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Deciphera Pharmaceuticals, LLC is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
1 of the studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05957367Deciphera Pharmaceuticals, LLCA Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gastrointestinal abnormalities including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles
Drug: Ripretinib
Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.
Drug: Sunitinib
Oral KIT/PDGFRA kinase inhibitor
Also known as: DCC-2618
Oral receptor tyrosine kinase (RTK) inhibitor
Also known as: Sutent
Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population
PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) GIST specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population
PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) Gastrointestinal stromal tumor (GIST) specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From date of randomization to earliest documented evidence of disease progression, or death due to any cause (up to 2.1 years)
Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population
ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: From confirmed CR or PR to disease progression (up to 1.74 years)
Objective Response Rate (ORR) in the All Patient (AP) Intent to Treat (ITT) Population
ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: From confirmed CR or PR to disease progression (up to 1.74 years)
Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population
OS was defined as the time from the date of randomization until death due to any cause.
Time frame: From date of randomization until death due to any cause (up to 3.33 years)
Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population
OS was defined as the time from the date of randomization until death due to any cause.
Time frame: From date of randomization until death due to any cause (up to 3.33 years)
| Milestone | Ripretinib | Sunitinib |
|---|---|---|
| Started | 226 | 227 |
| Completed | 190 | 203 |
| Not completed | 36 | 24 |
| Withdrew: Participants ongoing. | 36 | 24 |
PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) GIST specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | Ripretinib | Sunitinib |
|---|---|---|
| Progression Free Survival (PFS) in the KIT Exon 11 Intent to Treat (ITT) Population | 8.3 (6.8 to 13.3) | 7.0 (5.6 to 10.9) |
PFS is defined as the interval between the date of randomization and the earliest documented evidence of disease progression based on the independent radiologic review using modified RECIST Version 1.1-(mRECIST 1.1) Gastrointestinal stromal tumor (GIST) specific, or death due to any cause. Per mRECIST 1.1, progression was defined using mRECIST 1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| months | Ripretinib | Sunitinib |
|---|---|---|
| Progression Free Survival (PFS) in the All Patient (AP) Intent to Treat (ITT) Population | 8.0 (6.5 to 10.8) | 8.3 (6.3 to 11.0) |
ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Ripretinib | Sunitinib |
|---|---|---|
| Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population | 23.9 (17.6 to 31.2) | 14.6 (9.6 to 21.0) |
ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \>=30% decrease in the sum of the longest diameter of target lesions.
| percentage of participants | Ripretinib | Sunitinib |
|---|---|---|
| Objective Response Rate (ORR) in the All Patient (AP) Intent to Treat (ITT) Population | 21.7 (16.5 to 27.6) | 17.6 (12.9 to 23.2) |
OS was defined as the time from the date of randomization until death due to any cause.
| months | Ripretinib | Sunitinib |
|---|---|---|
| Overall Survival (OS) in the KIT Exon 11 Intent to Treat (ITT) Population | 34.0 (29.3 to NA) | 31.5 (29.4 to NA) |
OS was defined as the time from the date of randomization until death due to any cause.
| months | Ripretinib | Sunitinib |
|---|---|---|
| Overall Survival (OS) in the All Patient (AP) Intent to Treat (ITT) Population | 35.5 (29.3 to NA) | 30.9 (28.9 to NA) |
Collected over Collection of Adverse events started from the signing of informed consent through safety follow-up (up to 3.22 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ripretinib | 90/223 (40.4%) | 64/223 (28.7%) | 221/223 (99.1%) |
| Sunitinib | 95/221 (43%) | 61/221 (27.6%) | 219/221 (99.1%) |
| Event | Ripretinib | Sunitinib |
|---|---|---|
| Abdominal painGastrointestinal disorders | 6/223 | 6/221 |
| General physical health deteriorationGeneral disorders | 5/223 | 0/221 |
| COVID-19Infections and infestations | 5/223 | 2/221 |
| AnaemiaBlood and lymphatic system disorders | 4/223 | 2/221 |
| Urinary tract infectionInfections and infestations | 2/223 | 3/221 |
| Atrial fibrillationCardiac disorders | 3/223 | 0/221 |
| Small intestinal obstructionGastrointestinal disorders | 2/223 | 2/221 |
| DiarrhoeaGastrointestinal disorders | 1/223 | 2/221 |
| Gastrointestinal perforationGastrointestinal disorders | 0/223 | 2/221 |
| PyrexiaGeneral disorders | 0/223 | 2/221 |
| Event | Ripretinib | Sunitinib |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 144/223 | 18/221 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 61/223 | 116/221 |
| DiarrhoeaGastrointestinal disorders | 47/223 | 107/221 |
| HypertensionVascular disorders | 60/223 | 106/221 |
| FatigueGeneral disorders | 84/223 | 91/221 |
| StomatitisGastrointestinal disorders | 18/223 | 81/221 |
| MyalgiaMusculoskeletal and connective tissue disorders | 81/223 | 25/221 |
| ConstipationGastrointestinal disorders | 79/223 | 48/221 |
| Decreased appetiteMetabolism and nutrition disorders | 60/223 | 54/221 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 59/223 | 15/221 |
| Age, Customized(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| 18-64 years | 145 | 143 | 288 |
| 65-74 years | 56 | 66 | 122 |
| 75 years and older | 25 | 18 | 43 |
| Sex: Female, Male(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| Female | 87 | 85 | 172 |
| Male | 139 | 142 | 281 |
| Race/Ethnicity, Customized(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| Black or African American | 14 | 14 | 28 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 31 | 27 | 58 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| White | 148 | 152 | 300 |
| Not Report | 30 | 30 | 60 |
| Other | 1 | 2 | 3 |
| Eastern Cooperative Oncology Group (ECOG) Score at Screening(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| ECOG Score 0 | 131 | 128 | 259 |
| ECOG Score 1 | 92 | 98 | 190 |
| ECOG Score 2 | 3 | 1 | 4 |
| Mutation Type per Electronic Data Capture (EDC)(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| KIT Exon 9 | 31 | 28 | 59 |
| KIT Exon 11 | 167 | 169 | 336 |
| KIT/PDGFRA WT | 14 | 16 | 30 |
| Other KIT (absence of Exon 9 or 11)/PDGFRA | 14 | 14 | 28 |
| Intolerance to Imatinib per Electronic Data Capture (EDC)(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| Yes | 15 | 19 | 34 |
| No | 211 | 208 | 419 |
| Mutation Type per Interactive Response Technology (IRT)(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| KIT Exon 9 | 31 | 29 | 60 |
| KIT Exon 11 | 163 | 164 | 327 |
| KIT/PDGFRA wild type (WT) | 15 | 18 | 33 |
| Other KIT (absence of Exon 9 or 11)/PDGFRA | 17 | 16 | 33 |
| Intolerance to Imatinib per Interactive Response Technology (IRT)(Participants) | Ripretinib | Sunitinib | Total |
|---|---|---|---|
| Yes | 22 | 23 | 45 |
| No | 204 | 204 | 408 |
Showing the first 100 of 121 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Sep 2021, 30 months.
Results were first posted in Jan 2024, 2 years 4 months after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ripretinib
Gastrointestinal Stromal Tumors →
Deciphera Pharmaceuticals, LLC →